Zencore Biologics
PrivateLast Round
Series C
Extension
Aug 19, 2022
Total Funding Raised
$335.74M
Company Overview
Zencore Biologics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series C Extension round in August 2022.
Zencore Biologics is a biotechnology company providing comprehensive contract development and manufacturing (CDMO) services that support pharmaceutical enterprises in the development and production of macromolecular drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment, Quality Management
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zencore Biologics Comparables
Compare Zencore Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 甲贝医药科技有限公司 | 94% | |
| Chime Biologics | 93% | |
| Intellective Biologics (Suzhou) Co., Ltd. | 91% |
For institutional investors. Book with your work email.
Zencore Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Aug 19, 2022 | ||||
| Series C | Jan 25, 2022 | ||||
| Series C | Oct 27, 2021 | ||||
| Series B | Mar 22, 2021 | ||||
| Series A | Mar 31, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zencore Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IDG Capital | Series C, Series A, Series B |
| Korea Investment Partners | Series A |
| 招银国际金融有限公司 | Series B |
| Guoke Jiahe Capital | Series B |
| China International Capital Corporation | Series C Extension |
| Lingang Blue Bay Capital | Series C Extension |
| LYFE Capital | Series C, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2026
Monthly visitors increased 66% MoM, reaching 2.9K.
- Jan 21, 2026
Monthly visitors increased 49% MoM.
For institutional investors. Book with your work email.
Zencore Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zencore Biologics's valuation, stock price, and market status.
Is Zencore Biologics a public or private company?
Zencore Biologics is a private company.
What is the current stock price of Zencore Biologics?
Zencore Biologics is a private company, so its shares have no public market price. Caplight tracks Zencore Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zencore Biologics worth (valuation)?
Valuation information for Zencore Biologics is not publicly available.
Can I buy Zencore Biologics stock?
Zencore Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zencore Biologics's last funding round?
Zencore Biologics's most recent funding round was Series C Extension on August 19, 2022.
Who are the main investors in Zencore Biologics?
Key investors in Zencore Biologics include IDG Capital, LYFE Capital, Goldman Sachs Growth Equity, Goldman Sachs Asset Management, Sofina.
Will Zencore Biologics IPO soon?
No public IPO plans have been announced for Zencore Biologics.
How can I track Zencore Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Zencore Biologics's shares on secondary markets.